NCT03083574 - Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2023

Conditions

Refractory Chronic Graft Versus Host Disease (cGVHD)

Interventions

DEVICE

Photopheresis Theraflex ECP™

The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.

Trial Locations (8)

1000

RECRUITING

Institut Jules Bordet, Brussels

1090

RECRUITING

Universitair Ziekenhuis Brussel, Jette

1200

RECRUITING

Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert

2060

RECRUITING

Ziekenhuis Netwerk Antwerpen, Antwerp

2650

RECRUITING

Universitair Ziekenhuis Antwerpen, Edegem

4000

RECRUITING

CHU Liège, Liège

8000

RECRUITING

AZ Sint-Jan Brugge, Bruges

NOT_YET_RECRUITING

Universitair Ziekenhuis Gent, Ghent